Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03123159 · ClinicalTrials.gov registry record
Clinical Performance Evaluation of DxN HBV Assay
A clinical trial, sponsored by Beckman Coulter.
- Terminated
- Registry status
- 60
- Enrollment target
NCT03123159 is a clinical trial that was terminated before completion, run by Beckman Coulter. The registered enrollment target is 60 participants.
The verdict
NCT03123159 was terminated before completion, sponsored by Beckman Coulter.
- TERMINATED
- Registry status
- 60 participants
- Enrollment target
Study Summary
The DxN Hepatitis B Virus (HBV) Assay is an in vitro diagnostic assay intended as an aid in the management of HBV-infected individuals undergoing antiviral therapy. The purpose of the study is to establish the clinical performance of the DxN HBV Assay for plasma samples in the intended use population.
Interventions
- DIAGNOSTIC_TEST DxN HBV Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-05-27 |
| Est. Completion | 2017-08-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03123159
The ClinicalTrials.gov registry entry for NCT03123159 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beckman Coulter, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DxN HBV Assay is the first listed.
NCT03123159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03123159 about?
NCT03123159 is a clinical study titled "Clinical Performance Evaluation of DxN HBV Assay". The DxN Hepatitis B Virus (HBV) Assay is an in vitro diagnostic assay intended as an aid in the management of HBV-infected individuals undergoing antiviral therapy. The purpose of the study is to establish the clinical performance of the DxN HBV Assay for plasma samples in the intended use populatio...
What is the current status of trial NCT03123159?
This trial is currently terminated. The enrollment target is 60 participants. The study started on 2014-05-27. Estimated completion is 2017-08-30.
What interventions are being tested in trial NCT03123159?
The interventions under investigation include: DxN HBV Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03123159?
This trial is sponsored by Beckman Coulter, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.